Arterial Hypertension Clinical Trials

93 recruitingLast updated: June 18, 2026

There are 93 actively recruiting arterial hypertension clinical trials across 42 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Nashville, Tennessee, United States, Aurora, Colorado, United States, Durham, North Carolina, United States. Updated daily from ClinicalTrials.gov.


Arterial Hypertension Trials at a Glance

93 actively recruiting trials for arterial hypertension are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Nashville, Aurora, and Durham. Lead sponsors running arterial hypertension studies include University of Sao Paulo General Hospital, Vanderbilt University Medical Center, and Bastiaan Driehuys.

Browse arterial hypertension trials by phase

Treatments under study

About Arterial Hypertension Clinical Trials

Looking for clinical trials for Arterial Hypertension? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Arterial Hypertension trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Arterial Hypertension clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 93 trials

Recruiting
Phase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC815 enrolled119 locationsNCT07218029
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension
Insmed Incorporated344 enrolled2 locationsNCT07481981
Recruiting
Phase 2

Spironolactone for Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
National Institutes of Health Clinical Center (CC)70 enrolled1 locationNCT01712620
Recruiting
Phase 1

Study of Intravenous ZMA001 in Healthy Subjects

Pulmonary Arterial Hypertension PAH
National Heart, Lung, and Blood Institute (NHLBI)96 enrolled1 locationNCT05967299
Recruiting
Phase 4

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

Pulmonary Arterial Hypertension
Sheffield Teaching Hospitals NHS Foundation Trust40 enrolled1 locationNCT05825417
Recruiting
Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Pulmonary Arterial Hypertension PAHPulmonary Hypertension, Interstitial Lung Disease
AllRock Bio, Inc.40 enrolled19 locationsNCT07175038
Recruiting

Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease
Vanderbilt University Medical Center75 enrolled1 locationNCT05462574
Recruiting
Phase 2

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension PAH
Regeneron Pharmaceuticals99 enrolled6 locationsNCT07318597
Recruiting

A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

Pulmonary Arterial HypertensionIntrauterine Growth RestrictionHypertensive Disorder of Pregnancy
Massachusetts General Hospital27 enrolled2 locationsNCT07312227
Recruiting
Phase 1Phase 2

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.120 enrolled32 locationsNCT07593027
Recruiting
Phase 3

COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

ComorbiditiesCardiovascular Disease (CVD)Pulmonary Arterial Hypertension PAH
Assistance Publique - Hôpitaux de Paris186 enrolled1 locationNCT07245680
Recruiting
Not Applicable

EFFECTS OF PROPOLIS AND ROYAL JELLY SUPPLEMENTATION ON INFLAMMATORY AND OXIDATIVE STRESS MARKERS IN PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION

Inflammationsystemic arterial hypertension
Universidade Federal Fluminense48 enrolled1 locationNCT07596966
Recruiting
Not Applicable

Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Golden Jubilee National Hospital40 enrolled1 locationNCT07366879
Recruiting
Phase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension
Inhibikase Therapeutics486 enrolled2 locationsNCT07365332
Recruiting
Phase 2

A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd48 enrolled6 locationsNCT06846554
Recruiting
Phase 2

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Pulmonary Arterial HypertensionRight Ventricular DysfunctionRight Heart Failure+1 more
University of Washington60 enrolled1 locationNCT06053580
Recruiting
Not Applicable

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

Genetic TestingPulmonary Arterial HypertensionHeart Defects, Congenital
Universitaire Ziekenhuizen KU Leuven21 enrolled1 locationNCT02691689
Recruiting
Phase 1Phase 2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals232 enrolled85 locationsNCT06649110
Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

ObesityCardiovascular DiseasesChronic Kidney Diseases+8 more
Swiss Tropical & Public Health Institute1,200 enrolled1 locationNCT05881447
Recruiting
Phase 1

A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension PAH
Joseph C. Wu15 enrolled1 locationNCT06872112